Intu Diagnostics Raises $1.2M for Lab-Free Testing

Jan de Vries · 2026-06-26

A German startup is bringing the doctor's office to your doorstep with a pocket-sized, power-free diagnostic platform. Intu Diagnostics, based in Leipzig, just closed a $1.2 million strategic bridge round, pushing its total funding past $3.3 million. This isn't just another health tech raise — it's a step toward making lab-quality testing available anywhere, from your living room to remote clinics without electricity. ### The Lab That Fits in Your Pocket Intu Diagnostics is building what they call 'LAB-TO-GO': a device that delivers molecular diagnostics without needing a physical lab, a power grid, or specialized staff. Think of it like this: instead of mailing a sample to a central facility and waiting days for results, you get reliable answers on the spot. The company says their platform brings "a doctor's office level of reliability straight to the patient's door." The bridge round was backed by BSV Ventures, SAB (Saxonian Development Bank), and a group of business angels. The money will go toward strengthening their intellectual property, running pilot manufacturing trials, and gearing up for a larger Seed round. ### Why Lab-Free Matters Now Traditional diagnostics rely on centralized labs that are expensive to run and hard to access in rural or low-resource areas. Intu's technology removes those barriers. Their first application targets HPV testing in women's health — an area where early, accessible screening can save lives. But the platform is designed to adapt to multiple infectious diseases, potentially creating a whole new infrastructure for decentralized testing. Here's what sets them apart: - No need for electricity or specialized equipment - Pocket-sized and portable - Molecular-level accuracy without a lab - Designed for home, clinic, or field use ### The Bigger Picture in Health Tech Funding Intu's raise is part of a broader wave in diagnostics and molecular pathology. In 2026, funding in this space hit around $91 million, including Intu's latest round. Comparable companies include: - ShanX Medtech: $26 million for in-vitro antimicrobial testing - Xyall: $8.2 million for molecular pathology automation - Moonlight AI: $3 million for AI-enabled clinical diagnostics - Xsensio: $6.5 million for continuous biochemical monitoring In Germany, Würzburg-based NanoStruct raised $2.8 million for rapid bacterial detection, making it the closest same-country example. ### From Spin-Off to Scale-Up Founded in 2023 as a spin-off from the Fraunhofer Society, Intu Diagnostics is tackling one of healthcare's biggest pain points: making high-quality testing accessible where it's needed most. Their technology combines molecular-level diagnostic quality with full lab independence. That means no more waiting days for results, no more shipping samples across the country, and no more relying on centralized facilities that can't reach everyone. The company's platform is built for versatility. Beyond HPV, it can be adapted for other infectious diseases, creating a potential network of decentralized testing that could transform how we approach public health. ### What's Next for Intu With this bridge round, Intu is focused on key milestones: protecting their IP, proving their manufacturing process works, and validating their technology in real-world settings. These steps will set the stage for their upcoming Seed round, where they'll likely look for larger partners to help bring LAB-TO-GO to market. The vision is clear: diagnostics shouldn't be limited by geography or infrastructure. Intu Diagnostics is working to make lab-quality testing as simple as carrying a device in your pocket. And with $3.3 million in total funding, they're well on their way.